Citation only
via Europe PMC
Herbal Therapeutics in Osteoporosis: Mechanisms, Evidence, and Translational Potential.
Vafadar Moradi E, Vossoughinia S, Yazdanpanah Z, Sobhani H, Jalali J, Ghasemzadeh Rahbardar M.
Phytotherapy research : PTR · 2026
Cellular senescence
Chronic inflammation
Cell culture / in vitro
Human
Preclinical / animal
In vitro
Review
Abstract
Osteoporosis is a chronic bone disease marked by reduced density and increased fracture risk. Current treatments face limitations in safety, efficacy, and long-term adherence, prompting interest in alternative therapies. Herbal medicine, with its bioactive compounds and historical use, offers potential for bone health support. This review explores the role of Chrysanthemum morifolium, Crocus sativus, Eriobotrya japonica, Ficus carica, Glycine max, Olea europaea, Salvia rosmarinus, and Zingiber officinale in preventing and managing osteoporosis. Relevant studies were identified through comprehensive searches of Google Scholar, PubMed, Scopus, and Web of Science, without time restriction up to October 2025. Included literature encompassed in vitro experiments, in vivo animal models, and clinical trials investigating herbal interventions targeting bone loss and osteoporosis-related mechanisms. The reviewed botanicals modulate key molecular pathways involved in bone remodeling, including RANKL/NFATc1, MAPKs, NF-κB, Sirt1, Nrf2, BMP/Smad, Wnt/β-catenin, and XPO5-microRNA axes. Their bioactive constituents exert antioxidant, anti-inflammatory, anti-apoptotic, anti-senescent, and hormone-modulating effects, collectively promoting osteoblast differentiation and suppressing osteoclastogenesis. Several agents, such as crocin, safranal, and ursolic acid, demonstrated dual-action profiles and favorable safety in preclinical models, with emerging evidence supporting their immunomodulatory and angiogenic roles. Herbal therapeutics offer a multi-targeted, biologically harmonious approach to osteoporosis management. This review provides a mechanistic synthesis and translational framework for future research, highlighting their potential as adjunctive therapies, especially in aging populations. Standardization, clinical validation, and interdisciplinary collaboration are essential to advance these botanicals from bench to bedside.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.1002/ptr.70457
- Canonical
- link ↗
- Fetched
- 2026-10-10 MST
Cite this
APA
E, V.M., S, V., Z, Y., H, S., J, J., & M., G.R. (2026). Herbal Therapeutics in Osteoporosis: Mechanisms, Evidence, and Translational Potential. <em>Phytotherapy research : PTR</em>. https://doi.org/10.1002/ptr.70457
Vancouver
E VM, S V, Z Y, H S, J J, M. GR. Herbal Therapeutics in Osteoporosis: Mechanisms, Evidence, and Translational Potential. Phytotherapy research : PTR. 2026. doi:10.1002/ptr.70457.
BibTeX
@article{vafadar2026Herbal,
title = {Herbal Therapeutics in Osteoporosis: Mechanisms, Evidence, and Translational Potential.},
author = {Vafadar Moradi E and Vossoughinia S and Yazdanpanah Z and Sobhani H and Jalali J and Ghasemzadeh Rahbardar M.},
journal = {Phytotherapy research : PTR},
year = {2026},
doi = {10.1002/ptr.70457},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Biomedical Journal 2023
Open access · CC-BY
Impact of fasting & ketogenic interventions on the NLRP3 inflammasome: A narrative review
Frontiers in pharmacology 2026
Open access · OA
Mechanistic intersections of empagliflozin and nebivolol in aging-associated redox and inflammatory pathways.
Foods 2026
Open access · CC-BY
Apple Pomace as a Promising By-Product with High Antioxidant Potential in the Prevention of Aging Processes
International Journal of Sciences and Innovation Engineering 2025
Open access · CC-BY
Pharmacology of Senolytics: Targeting Cellular Aging in Chronic Diseases
Kidney International Reports 2021
Open access · CC-BY
Chronic Inflammation in Chronic Kidney Disease Progression: Role of Nrf2
Pharmaceuticals (Basel, Switzerland) 2026
Citation only